サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1292335

免疫組織化学の世界市場：用途別 (診断、研究、法医学)・エンドユーザー別の将来予測 (2028年まで)

Immunohistochemistry Market by Product, Application (Diagnostics, Research, Forensic), End Users - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 399 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
免疫組織化学の世界市場：用途別 (診断、研究、法医学)・エンドユーザー別の将来予測 (2028年まで)
出版日: 2023年06月09日
発行: MarketsandMarkets
ページ情報: 英文 399 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の免疫組織化学 (IHC) の市場規模は、2023年の32億米ドルから2028年には47億米ドルに達し、予測期間中 (2023年～2028年) に7.4%のCAGRで成長すると予測されています。

市場成長の主な促進要因は、がんの有病率の増加と、がんの診断や管理におけるIHC検査の大々的な活用です。また、コンパニオン診断薬の開発や、コンパニオン診断薬とIHC検査の統合は、個別化医療を促進し、医薬品開発と承認プロセスを支援し、市場の可能性を拡大し、患者の転帰を改善し、研究協力を促し、免疫組織化学市場に成長機会をもたらしています。

"試薬の種類別では、組織染色剤が最大のシェアを占める"

2022年には、免疫組織化学用の組織染色剤が最大のシェアを占めています。免疫組織化学では、標的の相対的局在は、多重染色技術の助けを借りて、1枚のスライドですべての相対的標的を可視化することによって得ることができます。多重染色とは、1枚のスライド上で2つ以上の標的を検出することであり、逐次染色、同時染色、色素を用いた多段階染色によって行うことができます。したがって、1つの組織染色剤で抗原部位を多重染色できる高度な能力は、実験的かつ使いやすい利点をもたらし、これが組織染色剤市場を牽引すると予想されます。

"用途別では、研究用途が第2位のシェアを占める"

2022年には、研究用途が第2位のシェアを占めました。研究用途におけるIHCには、抗腫瘍薬開発やバイオマーカー探索が含まれます。IHCは、正常細胞や異常細胞における発現の変化を研究するために、特定のタンパク質の発現や膜、細胞質、核内でのタンパク質の共局在を調べるのに役立ちます。研究用途に使用される高スループットの自動IHCプラットフォームは、スライド間の染色の均一性を維持するのに役立ちます。このような利点から、IHC技術は発生学研究、幹細胞研究、薬物検査にも広く用いられています。

"アジア太平洋：免疫組織化学市場で最も急速に成長している地域"

アジア太平洋地域は高成長市場であり、研究・臨床応用において最新の技術的に高度な製品 (アッセイや診断キットのような) が急速に採用されているのが特徴です。この要因は、同地域における老人人口の増加と相まって、急成長の主要な促進要因となっています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 免疫組織化学 (IHC) 市場の不確実性の要素
  • 顧客のビジネスに影響を与える動向/混乱
  • 価格分析
  • バリューチェーン分析
  • エコシステム分析
  • 技術分析
  • 特許分析
  • 規制分析
  • ポーターのファイブフォース分析
  • 主な会議とイベント (2023年～2024年)
  • 主要な利害関係者と購入基準

第6章 免疫組織化学市場：製品別

  • イントロダクション
  • 抗体
    • 一次抗体
    • 二次抗体
  • 試薬
    • 組織染色剤
    • ブロッキング血清と試薬
    • 発色基質
    • 固定試薬
    • 希釈剤
    • 有機溶剤
    • タンパク質分解酵素
    • その他の試薬
  • 装置
    • スライド染色システム
    • 組織処理システム
    • スライドスキャナー
    • その他の設備
  • キット
    • ヒト免疫組織化学キット
    • 動物免疫組織化学キット

第7章 免疫組織化学市場：用途別

  • イントロダクション
  • 診断用途
    • がん
    • 感染症
    • 腎臓病
    • 自己免疫疾患
    • 神経疾患
    • その他の疾患
  • 研究用途
    • 医薬品の開発と試験
    • その他の研究用途
  • 法医学用途

第8章 免疫組織化学市場：エンドユーザー別

  • イントロダクション
  • 病院・診断検査室
  • 学術研究機関
  • その他のエンドユーザー

第9章 免疫組織化学市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • 概要
  • 主要企業が採用した勝者獲得のアプローチ
  • 市場シェア分析
  • 上位企業の収益シェア分析
  • 企業評価クアドラント
  • 企業評価クアドラント：スタートアップ/中小企業
  • 企業の製品フットプリント
  • 企業の地域フットプリント
  • スタートアップ/中小企業の競合ベンチマーキング
  • 競合シナリオ

第11章 企業プロファイル

  • 主要企業
    • F. HOFFMANN-LA ROCHE AG
    • DANAHER CORPORATION
    • AGILENT TECHNOLOGIES, INC.
    • THERMO FISHER SCIENTIFIC, INC.
    • MERCK KGAA
    • BIO-RAD LABORATORIES, INC.
    • BIO-TECHNE CORPORATION
    • ABCAM PLC
    • BECTON, DICKINSON AND COMPANY
    • PERKINELMER, INC.
    • TAKARA BIO, INC.
    • PHC HOLDINGS CORPORATION
    • CELL SIGNALING TECHNOLOGY, INC.
    • BIO SB, INC.
    • MILTENYI BIOTEC
    • SAKURA FINETEK JAPAN CO., LTD.
    • ENZO BIOCHEM, INC.
    • ORIGENE TECHNOLOGIES, INC.
  • その他の企業
    • EAGLE BIOSCIENCES, INC.
    • BIOCARE MEDICAL, LLC
    • ELABSCIENCE BIOTECHNOLOGY, INC.
    • BIOGENEX LABORATORIES
    • DIAGNOSTIC BIOSYSTEMS, INC.
    • HISTO-LINE LABORATORIES
    • ROCKLAND IMMUNOCHEMICALS, INC.
    • GENEMED BIOTECHNOLOGIES, INC.
    • CANDOR BIOSCIENCE GMBH

第12章 付録

目次
Product Code: BT 4780

The global immunohistochemistry market is projected to reach USD 4.7 billion by 2028 from USD 3.2 billion in 2023, at a CAGR of 7.4% during the forecast period of 2023 to 2028. Market growth is largely driven by increased prevalence of cancer and vast application of IHC test in the diagnosis and management of cancer. Also, development for companion diagnostics and the integration of companion diagnostics with IHC is facilitating personalized medicine, supporting drug development and approval processes, expanding market potential, improves patient outcomes, encouraging research collaboration, and providing growth opportunities for Immunohistochemistry Market.

Histological Stain is expected to account for the largest share for by reagents segment.

In 2022, immunohistochemistry histological stains market accounted for the largest share. In immunohistochemistry, the relative localization of the target can be obtained by visualizing all relative targets in one slide with the help of multiple staining techniques. Multiple staining is the detection of two or more targets on a single slide, and it can be done by sequential staining, simultaneous staining, and multi-step staining using dyes. Hence, the advanced ability to multiplex antigenic sites in a single tissue section presents an experimental and ease-of-use advantage, which is expected to drive the market for histological stains.

Research applications segment accounted for the second-largest share of the application segment

In 2022, research applications accounted for the second largest share. IHC in research applications includes anti-tumor drug development and biomarker discovery. IHC helps to investigate the expression of specific proteins and co-localization of proteins within the membrane, cytoplasm, or nucleus to study the altered expression in normal and abnormal cells, more specifically to investigate the cancer proteome. High-throughput automated IHC platforms used in research applications help to maintain the uniformity of staining between slides. Due to these advantages, IHC techniques are also widely used in developmental (embryological) studies, stem cell research, and drug testing.

Asia Pacific is the fastest growing region in the immunohistochemistry market

The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). Asia Pacific is the fastest growing region in as it is a high-growth market, which is characterized by the fast adoption of the latest technologically advanced products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population in the region are the key drivers for fast growth rate.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side - 30%
  • By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Prominent Players of the Immunohistochemistry market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).

Research Coverage:

This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, challenges and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising geriatric population and growing prevalence of cancer diseases to influence positive market growth, Technological advancements in IHC, Availability of reimbursements for IHC tests, and Adoption of digital pathology fueling the market growth), restraint (Availability of alternative technologies, High degree of consolidation), opportunities (Increasing demand for personalized medicine, Growing significance of companion diagnostics, Growth opportunities in emerging countries, and Application of Artificial intelligence in IHC), Challenges (Product failures and recalls, Stringent regulatory requirements, Lack of Standardization)
  • Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the Immunohistochemistry market across varied regions.
  • Market Diversification: Exhaustive information about new product, untapped geographies, recent developments, and investments in the Immunohistochemistry market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of IHC market and provides them information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 IHC MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 IHC MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 4 IHC MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
    • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
    • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    • FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • 2.3 MARKET GROWTH RATE PROJECTIONS
    • FIGURE 7 IHC MARKET (SUPPLY SIDE): CAGR PROJECTIONS
    • FIGURE 8 IHC MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
    • 2.3.1 DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RISK ANALYSIS
  • 2.6 RECESSION IMPACT
    • TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 3 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 4 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2022
    • FIGURE 12 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023 VS. 2028
    • FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
    • FIGURE 14 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE, BY END USER AND COUNTRY (2022)
    • FIGURE 15 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IHC MARKET IN 2022
  • 4.3 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE
    • FIGURE 16 PRIMARY ANTIBODIES SEGMENT TO LEAD IHC ANTIBODIES MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 IHC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
    • TABLE 5 IHC MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising geriatric population and growing prevalence of cancer
    • TABLE 6 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION (2022-2050)
    • FIGURE 18 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2020
      • 5.2.1.2 Technological advancements in IHC
      • 5.2.1.3 Availability of reimbursements for IHC tests
    • TABLE 7 CPT CODES FOR IHC PROCEDURES
      • 5.2.1.4 Adoption of digital pathology
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Availability of alternative technologies
      • 5.2.2.2 High degree of consolidation
    • TABLE 8 MAJOR ACQUISITIONS IN MARKET, 2020-2023
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for personalized medicine
    • FIGURE 19 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015-2022
      • 5.2.3.2 Growing significance of companion diagnostics
      • 5.2.3.3 Growth opportunities in emerging countries
      • 5.2.3.4 Application of artificial intelligence in IHC
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Product failures and recalls
      • 5.2.4.2 Stringent regulatory requirements
      • 5.2.4.3 Lack of standardization
  • 5.3 ELEMENTS OF UNCERTAINTY IN IHC MARKET
    • FIGURE 20 IHC MARKET: SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 21 REVENUE SHIFT & NEW REVENUE POCKETS FOR IHC PROVIDERS
  • 5.5 PRICING ANALYSIS
    • TABLE 9 AVERAGE SELLING PRICE OF SOME IHC EQUIPMENT, REAGENTS, AND KITS (2022)
    • 5.5.1 AVERAGE SELLING PRICE TRENDS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS OF IHC MARKET: RAW MATERIAL AND MANUFACTURING PHASE TO CONTRIBUTE MAXIMUM VALUE
    • 5.6.1 RESEARCH AND PRODUCT DEVELOPMENT
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 23 IHC MARKET: ECOSYSTEM ANALYSIS
    • TABLE 10 SUPPLY CHAIN ECOSYSTEM
  • 5.8 TECHNOLOGY ANALYSIS
  • 5.9 PATENT ANALYSIS
    • FIGURE 24 IHC MARKET: PATENT ANALYSIS, 2014-2023
    • TABLE 11 INDICATIVE LIST OF PATENTS IN IHC MARKET
  • 5.10 REGULATORY ANALYSIS
    • 5.10.1 US
    • TABLE 12 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
    • FIGURE 25 US: REGULATORY PROCESS FOR IVD DEVICES
    • 5.10.2 CANADA
    • FIGURE 26 CANADA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.10.3 EUROPE
    • TABLE 13 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 27 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
    • 5.10.4 JAPAN
    • FIGURE 28 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 14 JAPAN: CLASSIFICATION OF IVD REAGENTS
    • TABLE 15 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.10.5 CHINA
    • TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.10.6 INDIA
    • FIGURE 29 INDIA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.10.7 BRAZIL
    • FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 17 IMPACT OF PORTER'S FIVE FORCES ANALYSIS ON IHC MARKET
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF BUYERS
    • 5.11.4 BARGAINING POWER OF SUPPLIERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 18 IMMUNOHISTOCHEMISTRY MARKET: LIST OF CONFERENCES AND EVENTS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS
    • FIGURE 32 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS

6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 19 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 ANTIBODIES
    • TABLE 20 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 21 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • 6.2.1 PRIMARY ANTIBODIES
      • 6.2.1.1 Wide applications in diagnostics and research to support demand for primary antibodies
    • TABLE 25 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 26 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 SECONDARY ANTIBODIES
      • 6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to fuel market
    • TABLE 29 IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 30 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 REAGENTS
    • TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 6.3.1 HISTOLOGICAL STAINS
      • 6.3.1.1 Developments in concurrent detection of multiple antigenic sites and cancer disease progression studies to propel market
    • TABLE 38 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.2 BLOCKING SERA AND REAGENTS
      • 6.3.2.1 Blocking sera and reagents to prevent nonspecific binding and reduce background noise & potentially false-positive results
    • TABLE 42 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 43 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.3 CHROMOGENIC SUBSTRATES
      • 6.3.3.1 Chromogenic substrates segment to register highest growth during forecast period
    • TABLE 46 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.4 FIXATION REAGENTS
      • 6.3.4.1 North America projected to be largest market for fixation reagents
    • TABLE 50 IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.5 DILUENTS
      • 6.3.5.1 Need of diluents for preparation of antibody solutions to promote market growth
    • TABLE 54 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 55 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.6 ORGANIC SOLVENTS
      • 6.3.6.1 Organic solvents to prevent physical damage in specimens and improve clarity while visualizing tissue samples
    • TABLE 58 IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.7 PROTEOLYTIC ENZYMES
      • 6.3.7.1 Proteolytic enzymes improve accessibility of target antibodies
    • TABLE 62 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.8 OTHER REAGENTS
    • TABLE 66 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 EQUIPMENT
    • TABLE 70 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 71 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • 6.4.1 SLIDE-STAINING SYSTEMS
      • 6.4.1.1 Development of high-throughput staining systems to drive market growth
    • TABLE 75 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 76 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.4.2 TISSUE PROCESSING SYSTEMS
      • 6.4.2.1 Technological advancements and need for automation due to lack of skilled workforce to fuel market
    • TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.4.3 SLIDE SCANNERS
      • 6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth
    • TABLE 83 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 84 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021-2028 USD MILLION)
    • TABLE 86 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.4.4 OTHER EQUIPMENT
    • TABLE 87 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 KITS
    • TABLE 91 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 92 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • 6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
      • 6.5.1.1 Increasing focus on cancer research to fuel market growth
    • TABLE 96 IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 97 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
      • 6.5.2.1 Increasing preclinical drug testing to boost market
    • TABLE 100 IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 101 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 103 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021-2028 (USD MILLION)

7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 104 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 DIAGNOSTIC APPLICATIONS
    • TABLE 105 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 106 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 107 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 108 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 109 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • 7.2.1 CANCER
      • 7.2.1.1 Rise in incidence rate of cancer and growing use of IHC tests for cancer diagnostics to drive market
    • TABLE 110 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
    • TABLE 111 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 112 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.2 INFECTIOUS DISEASES
      • 7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market
    • TABLE 115 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
    • TABLE 116 IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 117 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 118 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.3 NEPHROLOGICAL DISEASES
      • 7.2.3.1 Wide application of IHC in transplant rejection expected to support market growth
    • TABLE 120 IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 121 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.4 AUTOIMMUNE DISEASES
      • 7.2.4.1 Availability of numerous primary antibodies and rapid processing of results to drive market
    • TABLE 124 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 125 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 126 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.5 NEUROLOGICAL DISEASES
      • 7.2.5.1 Increasing global burden of neurological diseases to propel market growth
    • TABLE 128 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR CENTRAL NERVOUS SYSTEM
    • TABLE 129 IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.6 OTHER DISEASES
    • TABLE 133 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 134 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 135 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 RESEARCH APPLICATIONS
    • TABLE 137 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 139 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 141 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • 7.3.1 DRUG DEVELOPMENT & TESTING
      • 7.3.1.1 Quantitative image analysis makes IHC techniques ideal for drug testing
    • TABLE 142 IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 143 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 144 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 145 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.2 OTHER RESEARCH APPLICATIONS
    • TABLE 146 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 147 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 148 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 149 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 FORENSIC APPLICATIONS
    • TABLE 150 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 151 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 152 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 153 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 154 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 HOSPITALS & DIAGNOSTIC LABORATORIES
    • 8.2.1 RISE IN SPECIALTY DIAGNOSTIC TESTS IN LABORATORIES AND IN-HOUSE DIAGNOSTIC PROCEDURES IN HOSPITALS TO DRIVE MARKET
    • TABLE 155 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 156 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 157 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 158 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 ACADEMIC & RESEARCH INSTITUTES
    • 8.3.1 GROWING APPLICATION OF IHC TESTS FOR DRUG DEVELOPMENT STUDIES TO POSITIVELY IMPACT MARKET GROWTH
    • TABLE 159 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 160 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 161 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 162 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER END USERS
    • TABLE 163 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 164 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 165 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 166 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 167 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 33 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
    • TABLE 168 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 169 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 173 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 175 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 176 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Availability of reimbursements for FDA-approved immunohistochemistry products to promote market
    • TABLE 178 RECENT DEVELOPMENTS IN US IHC MARKET
    • TABLE 179 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 180 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 181 US: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 182 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 US: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 184 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 185 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 186 US: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 187 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Rise in cancer cases in Canada to propel market growth
    • TABLE 188 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 189 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 190 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 191 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 193 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 194 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 195 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 196 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.3 NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    • TABLE 197 RECENT DEVELOPMENTS IN EUROPEAN IHC MARKET
    • TABLE 198 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 199 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 200 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 201 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 202 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 203 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 204 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 206 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 207 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany to dominate European IHC market due to vast research pool and favorable reimbursement policies
    • TABLE 208 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 209 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 210 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 211 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 212 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 213 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 214 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 215 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 216 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.2 FRANCE
      • 9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market
    • TABLE 217 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 218 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 219 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 220 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 221 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 222 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 223 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 224 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 225 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.3 UK
      • 9.3.3.1 Increase in number of cancer research studies to support market growth
    • TABLE 226 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 227 UK: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 228 UK: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 229 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 230 UK: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 231 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 232 UK: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 233 UK: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 234 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 High incidence of cancer and rising geriatric population to support market growth in Italy
    • TABLE 235 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 236 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 237 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 238 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 239 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 240 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 241 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 242 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 243 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Spike in demand for personalized medicine to drive demand for IHC tests to find potential biomarkers
    • TABLE 244 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 245 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 246 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 247 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 248 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 249 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 250 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 251 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 252 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 253 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 254 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 255 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 256 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 257 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 258 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 259 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 260 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 261 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.7 EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    • FIGURE 34 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
    • TABLE 262 RECENT DEVELOPMENTS IN ASIA PACIFIC IHC MARKET
    • TABLE 263 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 264 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 266 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 267 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 268 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 269 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 270 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 271 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 Rise in product approvals and shift toward immunoassay diagnostics to fuel market growth
    • TABLE 273 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 274 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 275 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 276 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 277 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 278 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 279 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 280 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 281 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Advancing healthcare expenditure to drive market
    • TABLE 282 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 283 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 284 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 285 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 286 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 287 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 288 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 289 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 290 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 High-end pathology and diagnostic services to propel market in India
    • TABLE 291 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 292 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 293 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 294 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 295 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 296 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 297 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 298 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 299 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.4 AUSTRALIA
      • 9.4.4.1 Investment initiatives to drive market growth
    • TABLE 300 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 301 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 302 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 303 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 304 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 305 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 306 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 307 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 308 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.5 SOUTH KOREA
      • 9.4.5.1 Personalized medicine initiatives to fuel market growth
    • TABLE 309 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 310 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 311 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 312 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 313 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 314 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 315 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 316 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 317 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.6 REST OF ASIA PACIFIC
    • TABLE 318 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 319 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 320 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 321 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 322 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 323 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 324 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 325 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 326 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.7 ASIA PACIFIC: RECESSION IMPACT
  • 9.5 LATIN AMERICA
    • 9.5.1 SPIKE IN INCIDENCE OF CANCER IN LATIN AMERICA TO BOOST MARKET
    • TABLE 327 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 328 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 329 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 330 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 331 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 332 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 333 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 334 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 335 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.5.2 LATIN AMERICA: RECESSION IMPACT
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 GOVERNMENT INITIATIVES FOCUSED ON BOOSTING HEALTHCARE INFRASTRUCTURE DEVELOPMENT TO DRIVE MARKET
    • TABLE 336 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 337 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 338 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 339 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 340 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 341 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 342 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021-2028 (USD MILLION)
    • TABLE 343 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 344 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 35 IMMUNOHISTOCHEMISTRY MARKET: STRATEGIES ADOPTED BY KEY PLAYERS, 2020-2023
  • 10.3 MARKET SHARE ANALYSIS
    • FIGURE 36 IMMUNOHISTOCHEMISTRY MARKET: SHARE ANALYSIS OF KEY PLAYERS (2022)
  • 10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 37 IMMUNOHISTOCHEMISTRY MARKET: REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS FOR PAST FIVE YEARS
  • 10.5 COMPANY EVALUATION QUADRANT
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • FIGURE 38 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT, 2022
  • 10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 STARTING BLOCKS
    • 10.6.3 RESPONSIVE COMPANIES
    • 10.6.4 DYNAMIC COMPANIES
    • FIGURE 39 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
  • 10.7 COMPANY PRODUCT FOOTPRINT
    • TABLE 345 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT PORTFOLIO ANALYSIS (2022)
  • 10.8 COMPANY REGIONAL FOOTPRINT
    • TABLE 346 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL REVENUE MIX (2022)
  • 10.9 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 347 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 10.10 COMPETITIVE SCENARIO
    • TABLE 348 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT LAUNCHES, JANUARY 2020-MAY 2023
    • TABLE 349 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2020-MAY 2023
    • TABLE 350 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2020-MAY 2023

11 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
  • 11.1 KEY PLAYERS
    • 11.1.1 F. HOFFMANN-LA ROCHE AG
    • TABLE 351 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)
    • 11.1.2 DANAHER CORPORATION
    • TABLE 352 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.3 AGILENT TECHNOLOGIES, INC.
    • TABLE 353 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.4 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 354 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.5 MERCK KGAA
    • TABLE 355 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 44 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 11.1.6 BIO-RAD LABORATORIES, INC.
    • TABLE 356 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.7 BIO-TECHNE CORPORATION
    • TABLE 357 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
    • FIGURE 46 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.8 ABCAM PLC
    • TABLE 358 ABCAM PLC: BUSINESS OVERVIEW
    • FIGURE 47 ABCAM PLC: COMPANY SNAPSHOT (2022)
    • 11.1.9 BECTON, DICKINSON AND COMPANY
    • TABLE 359 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 11.1.10 PERKINELMER, INC.
    • TABLE 360 PERKINELMER, INC.: BUSINESS OVERVIEW
    • FIGURE 49 PERKINELMER, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.11 TAKARA BIO, INC.
    • TABLE 361 TAKARA BIO, INC.: BUSINESS OVERVIEW
    • FIGURE 50 TAKARA BIO, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.12 PHC HOLDINGS CORPORATION
    • TABLE 362 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 51 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.13 CELL SIGNALING TECHNOLOGY, INC.
    • TABLE 363 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
    • 11.1.14 BIO SB, INC.
    • TABLE 364 BIO SB, INC.: BUSINESS OVERVIEW
    • 11.1.15 MILTENYI BIOTEC
    • TABLE 365 MILTENYI BIOTEC: BUSINESS OVERVIEW
    • 11.1.16 SAKURA FINETEK JAPAN CO., LTD.
    • TABLE 366 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
    • 11.1.17 ENZO BIOCHEM, INC.
    • TABLE 367 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
    • FIGURE 52 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.18 ORIGENE TECHNOLOGIES, INC.
    • TABLE 368 ORIGENE TECHNOLOGIES, INC.: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 EAGLE BIOSCIENCES, INC.
    • TABLE 369 EAGLE BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • 11.2.2 BIOCARE MEDICAL, LLC
    • TABLE 370 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW
    • 11.2.3 ELABSCIENCE BIOTECHNOLOGY, INC.
    • TABLE 371 ELABSCIENCE BIOTECHNOLOGY, INC.: COMPANY OVERVIEW
    • 11.2.4 BIOGENEX LABORATORIES
    • TABLE 372 BIOGENEX LABORATORIES: COMPANY OVERVIEW
    • 11.2.5 DIAGNOSTIC BIOSYSTEMS, INC.
    • TABLE 373 DIAGNOSTIC BIOSYSTEMS, INC.: BUSINESS OVERVIEW
    • 11.2.6 HISTO-LINE LABORATORIES
    • TABLE 374 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
    • 11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
    • TABLE 375 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
    • 11.2.8 GENEMED BIOTECHNOLOGIES, INC.
    • TABLE 376 GENEMED BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • 11.2.9 CANDOR BIOSCIENCE GMBH
    • TABLE 377 CANDOR BIOSCIENCE GMBH: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.2 CUSTOMIZATION OPTIONS
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS